Literature DB >> 9667961

Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil.

U Beyer1, T Roth, P Schumacher, G Maier, A Unold, A W Frahm, H H Fiebig, C Unger, F Kratz.   

Abstract

One strategy for improving the selectivity and toxicity profile of antitumor agents is to design drug carrier systems employing soluble macromolecules or carrier proteins. Thus, five maleimide derivatives of chlorambucil were bound to thiolated human serum transferrin which differ in the stability of the chemical link between drug and spacer. The maleimide ester derivatives 1 and 2 were prepared by reacting 2-hydroxyethylmaleimide or 3-maleimidophenol with the carboxyl group of chlorambucil, and the carboxylic hydrazone derivatives 5-7 were obtained through reaction of 2-maleimidoacetaldehyde, 3-maleimidoacetophenone, or 3-maleimidobenzaldehyde with the carboxylic acid hydrazide derivative of chlorambucil. The alkylating activity of transferrin-bound chlorambucil was determined with the aid of 4-(4-nitrobenzyl)pyridine (NBP) demonstrating that on average 3 equivalents were protein-bound. Evaluation of the cytotoxicity of free chlorambucil and the respective transferrin conjugates in the MCF7 mammary carcinoma and MOLT4 leukemia cell line employing a propidium iodide fluorescence assay demonstrated that the conjugates in which chlorambucil was bound to transferrin through non-acid-sensitive linkers, i.e., an ester or benzaldehyde carboxylic hydrazone bond, were not, on the whole, as active as chlorambucil. In contrast, the two conjugates in which chlorambucil was bound to transferrin through acid-sensitive carboxylic hydrazone bonds were as active as or more active than chlorambucil in both cell lines. Especially, the conjugate in which chlorambucil was bound to transferrin through an acetaldehyde carboxylic hydrazone bond exhibited IC50 values which were approximately 3-18-fold lower than those of chlorambucil. Preliminary toxicity studies in mice showed that this conjugate can be administered at higher doses in comparison to unbound chlorambucil. The structure-activity relationships of the transferrin conjugates are discussed with respect to their pH-dependent acid sensitivity, their serum stability, and their cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667961     DOI: 10.1021/jm9704661

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.

Authors:  U Beyer; B Rothern-Rutishauser; C Unger; H Wunderli-Allenspach; F Kratz
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

3.  PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.

Authors:  Tae Hyung Kim; Young Gi Jo; Hai Hua Jiang; Sung Mook Lim; Yu Seok Youn; Seulki Lee; Xiaoyuan Chen; Youngro Byun; Kang Choon Lee
Journal:  J Control Release       Date:  2012-07-21       Impact factor: 9.776

4.  Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Biother Radiopharm       Date:  2011-12-22       Impact factor: 3.099

Review 5.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

6.  Theranostic Polyaminocarboxylate-Cyanine-Transferrin Conjugate for Anticancer Therapy and Near-Infrared Optical Imaging.

Authors:  Chi Soo Kang; Siyuan Ren; Xiang Sun; Hyun-Soon Chong
Journal:  ChemMedChem       Date:  2016-09-14       Impact factor: 3.466

7.  Environment-Responsive Polymers for Coating of Pharmaceutical Nanocarriers(,).

Authors:  A A Kale; V P Torchilin
Journal:  Polym Sci Ser A Chem Phys       Date:  2009-06

Review 8.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

9.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

10.  An efficient targeted drug delivery through apotransferrin loaded nanoparticles.

Authors:  Athuluri Divakar Sai Krishna; Raj Kumar Mandraju; Golla Kishore; Anand Kumar Kondapi
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.